Author
Yee Chao
Other affiliations: National Yang-Ming University, University of California, Los Angeles
Bio: Yee Chao is an academic researcher from Taipei Veterans General Hospital. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 44, co-authored 294 publications receiving 9275 citations. Previous affiliations of Yee Chao include National Yang-Ming University & University of California, Los Angeles.
Topics: Hepatocellular carcinoma, Medicine, Cancer, Internal medicine, Sorafenib
Papers published on a yearly basis
Papers
More filters
University of Ulsan1, Osaka University2, Taipei Veterans General Hospital3, University Health System4, Chang Gung University5, Samsung Medical Center6, National Taiwan University7, Korea University8, China Medical University (Taiwan)9, Kindai University10, Seoul National University Bundang Hospital11, Keio University12, Kyungpook National University13, Japanese Foundation for Cancer Research14, Seoul National University Hospital15, Yonsei University16, National Cheng Kung University17, National Health Research Institutes18
TL;DR: In this phase 3 study, the survival benefits indicate that nivolumab might be a new treatment option for heavily pretreated patients with advanced gastric or gastro-oesophageal junction cancer.
1,512 citations
University of California, Los Angeles1, University of Ulsan2, Kindai University3, Samsung Medical Center4, Taipei Veterans General Hospital5, Chiba University6, Pontifical Catholic University of Chile7, The Chinese University of Hong Kong8, Princess Margaret Cancer Centre9, Merck & Co.10, Harvard University11, National Taiwan University12
TL;DR: The results are consistent with those of KEYNOTE-224, supporting a favorable risk-to-benefit ratio for pembrolizumab in this population, and one-sided significance thresholds for OS and PFS did not reach statistical significance per specified criteria.
Abstract: PURPOSEPembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). KEYNOTE-240 evaluated ...
1,056 citations
TL;DR: Pembrolizumab did not significantly improve overall survival compared with paclitaxel as second-line therapy for advanced gastric or gastro-oesophageal junction cancer with PD-L1 CPS of 1 or higher and had a better safety profile than pac litaxel.
868 citations
University of Birmingham1, Wayne State University2, National Taiwan University3, Chang Gung University4, Pusan National University5, Samsung Medical Center6, University of Paris-Est7, Sungkyunkwan University8, Kindai University9, Sichuan University10, Mahidol University11, Russian Academy12, Kyungpook National University13, Bristol-Myers Squibb14
TL;DR: Brivanib had an acceptable safety profile, but was less well-tolerated than sorafenib, and both agents had similar antitumor activity, based on secondary efficacy end points.
Abstract: Purpose Brivanib is a dual inhibitor of vascular-endothelial growth factor and fibroblast growth factor receptors that are implicated in the pathogenesis of hepatocellular carcinoma (HCC). Our multinational, randomized, double-blind, phase III trial compared brivanib with sorafenib as first-line treatment for HCC. Patients and Methods Advanced HCC patients who had no prior systemic therapy were randomly assigned (ratio, 1:1) to receive sorafenib 400 mg twice daily orally (n = 578) or brivanib 800 mg once daily orally (n = 577). Primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response rate (ORR), disease control rate (DCR) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), and safety. Results The primary end point of OS noninferiority for brivanib versus sorafenib in the per-protocol population (n = 1,150) was not met (hazard ratio [HR], 1.06; 95.8% CI, 0.93 to 1.22), based on the prespecified margin (upper CI limit for ...
644 citations
Icahn School of Medicine at Mount Sinai1, University of Barcelona2, French Institute of Health and Medical Research3, Institut Gustave Roussy4, Kindai University5, Asan Medical Center6, Samsung Medical Center7, Kyungpook National University Hospital8, Chang Gung University9, Taipei Veterans General Hospital10, University of Hong Kong11, Toronto General Hospital12, University of California, Los Angeles13, Bristol-Myers Squibb14
TL;DR: In patients with HCC who had been treated with sorafenib, brivanib did not significantly improve OS, and the observed benefit in the secondary outcomes of TTP and ORR warrants further investigation.
Abstract: Purpose Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular carcinoma (HCC). An unmet medical need persists for patients with HCC whose tumors do not respond to sorafenib or who cannot tolerate it. This multicenter, double-blind, randomized, placebo-controlled trial assessed brivanib in patients with HCC who had been treated with sorafenib. Patients and Methods In all, 395 patients with advanced HCC who progressed on/after or were intolerant to sorafenib were randomly assigned (2:1) to receive brivanib 800 mg orally once per day plus best supportive care (BSC) or placebo plus BSC. The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response rate (ORR), and disease control rate based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) and safety. Results Median OS was 9.4 months for brivanib and 8.2 mont...
521 citations
Cited by
More filters
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
7,851 citations
Kindai University1, University of California, Los Angeles2, Yonsei University3, University of Bologna4, California Pacific Medical Center5, Fourth Military Medical University6, Gdańsk Medical University7, University of Bordeaux8, Hannover Medical School9, Beatson West of Scotland Cancer Centre10, Eisai11, National Taiwan University12
TL;DR: Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma and the safety and tolerability profiles of lenvatinIB were consistent with those previously observed.
3,046 citations
01 Jan 2012
TL;DR: The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data.
Abstract: EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies recommended for patients with this type of cancer. This is the first European joint effort by the European Association for the Study of the Liver (EASL) and the European Organization for Research and Treatment of Cancer (EORTC) to provide common guidelines for the management of hepatocellular carcinoma. These guidelines update the recommendations reported by the EASL panel of experts in HCC published in 2001 [1]. Several clinical and scientific advances have occurred during the past decade and, thus, a modern version of the document is urgently needed. The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data. Users of these guidelines should be aware that the recommendations are intended to guide clinical practice in circumstances where all possible resources and therapies are available. Thus, they should adapt the recommendations to their local regulations and/or team capacities, infrastructure, and cost– benefit strategies. Finally, this document sets out some recommendations that should be instrumental in advancing the research and knowledge of this disease and ultimately contribute to improve patient care. The EASL–EORTC CPG on the management of hepatocellular carcinoma provide recommendations based on the level of evidence and the strength of the data (the classification of evidence is adapted from National Cancer Institute [2]) (Table 1A) and the strength of recommendations following previously reported systems (GRADE systems) (Table 1B).
2,594 citations
University of Barcelona1, University of Bologna2, Taipei Veterans General Hospital3, Chiba University4, Pierre-and-Marie-Curie University5, University of Cambridge6, Tianjin Medical University7, University of Lorraine8, Kindai University9, National Taiwan University10, Icahn School of Medicine at Mount Sinai11, Catalan Institution for Research and Advanced Studies12, University of California, Los Angeles13, Bayer Corporation14, Bayer15, Bayer HealthCare Pharmaceuticals16, Fourth Military Medical University17
TL;DR: Regorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenIB treatment, and future trials should explore combinations of regorAFenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafanib and regorafinib.
2,543 citations